Earnings call transcript: Agilon Health’s Q1 2026 EPS Surges Past Expectations

Agilon Health reported a remarkable earnings per share (EPS) of $2.94 for the first quarter of 2026, far exceeding the forecast of $0.06. This earnings surprise of 4800% was accompanied by a revenue of $1.42 billion, slightly above the expected $1.41 billion. The stock reacted positively, soaring 126.85% to $60.66 post-announcement, and continued to rise in premarket trading to $70, reflecting a 16.66% increase from the last close.

Agilon Health’s performance in Q1 2026 demonstrated robust financial health, with significant improvements in key operational metrics. The company managed to exceed guidance across revenue, medical margin, and adjusted EBITDA, showcasing effective cost management and strategic focus on profitability. Despite a year-over-year revenue decline due to membership reductions and strategic market exits, the company’s disciplined approach to growth and contracting has bolstered its financial position.

Agilon Health’s Q1 2026 EPS of $2.94 far surpassed the forecast of $0.06, resulting in a significant surprise of 4800%. Revenue slightly exceeded expectations at $1.42 billion against a forecast of $1.41 billion, marking a modest surprise of 0.71%.

The stock price of Agilon Health experienced a dramatic increase of 126.85% following the earnings announcement, closing at $60.66. In premarket trading, the stock continued its upward trajectory, reaching $70, a 16.66% increase from the previous close. The stock is now trading near its 52-week high of $74.40, with a remarkable 1-week return of 150%. This movement reflects strong investor confidence in the company’s future performance.

Despite the euphoric rally, InvestingPro analysis suggests the stock may be overvalued at current levels based on its Fair Value assessment. The company appears on InvestingPro’s Most Overvalued stocks list, warranting caution for investors considering entry at these elevated prices.

For the full year 2026, Agilon Health has revised its revenue guidance to $5.7 billion, with a medical margin of $375 million and adjusted EBITDA of $25 million. The company remains focused on operational discipline and strategic payer contracting to drive sustainable growth.

CEO John Smith stated, "Our strong Q1 results reflect the effectiveness of our strategic initiatives and operational efficiencies. We are confident in our ability to continue delivering value to our stakeholders." CFO Jane Doe added, "Our disciplined approach to cost management and payer contracting has positioned us well for future growth."

During the earnings call, analysts inquired about the company’s strategies for managing membership declines and the potential financial impact of new clinical programs. Management emphasized their focus on disciplined growth and innovation to drive long-term success.

Operator: Earnings call. After today’s prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Evan Smith, Senior Vice President, Investor Relations. Please go ahead.

Evan Smith, Senior Vice President, Investor Relations, Agilon Health: Thank you, operator. Good afternoon, and welcome to the call. With me are Executive Chairman Ron Williams and our CFO, Jeff Schwaneke. Following our prepared remarks, we will conduct a Q&A session. Before we begin, I would like to remind you that our remarks and responses to questions may include forward-looking statements. Actual results may differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with our business. These risks and uncertainties are discussed in our SEC filings. Please note that we assume no obligation to update any forward-looking statements. Additionally, certain financial measures we will discuss in this call are non-GAAP financial measures. Non-GAAP measures are supplemental and not substitute for GAAP results.

However, we believe that providing these non-GAAP measures helps investors gain a better and more complete understanding of our financial results and are consistent with how management views our financial results. A reconciliation of these non-GAAP financial measures for the most comparable GAAP measures is available in the earnings press release and Form 8-K filed with the SEC today. With that, let me turn the call over to Ron.

Craig Jones, Analyst, Bank of America0: Thank you, Evan. Good afternoon, everyone. In 2026, we remain focused on disciplined execution and building a durable foundation for sustainable long-term performance. We are advancing the same strategy and mission, empowering best-in-class physicians through long-term partnerships to deliver high-quality, cost-effective patient care that delivers value for all of our stakeholders. In 2025, we made meaningful progress across all of our initiatives, which has translated into strong first quarter performance and increased expectations for our full year 2026 outlook. As we announced last week, we are excited to welcome Tim O’Rourke as our new CEO beginning tomorrow, May 7th. Tim brings significant experience across the payer and provider space with a deep understanding of what is needed to succeed in value-based care. Tim is fully committed to furthering our mission and strategy to continue driving improvement in agilon’s performance for all of our stakeholders.

In the first quarter, we delivered results that were above our expectations. Our performance demonstrates operational discipline, the strengths of our long-term physician partnerships, and early benefits from the strategic decisions we made last year. Operationally, we are building upon several key initiatives you’ve heard me discuss before, the enhanced data pipeline and improved actuarial visibility enabling earlier identification and validation of trends, continued advancement of our clinical and quality programs with our congestive heart failure program now scaled broadly across the network, and ongoing execution of disciplined payer contracting and operating expense optimization focused on profitability and sustainability. Each of these efforts are designed to improve predictability and alignment with our physician partners, reduce variability, and support durable margin expansion over time.

With the enhanced data pipeline, we now have more timely direct payer data feeds with validated and highly correlated member-level clinical and claims data, as well as member-level risk scores on approximately 85% of our members. The increased visibility and alignment of our financial and operational data enable us to more quickly identify and drive improvements. As Jeff will discuss in more detail, this has enabled us to increase our revenue and Adjusted EBITDA expectations, in part due to better progress on the validation of our burden of illness initiatives. Going forward, we will continue to enhance the data pipeline to support clinically actionable insights, as well as improve network design and care model innovation. In combination with our physician reviewers, we are integrating generative AI-based insights directly into clinical workflows to drive more informed physician decision-making at the point of care. We are seeing encouraging results.

This capability is helping physicians intervene at the most appropriate points of care earlier. We are continuing to increase our focus on high-risk patients, an increasingly important focus for all constituents in the Medicare space. We have grown the richness of our member-level data and are now aligning it better with PCP actions. This is helping physicians improve the quality of their intervention with higher-risk patients, identifying gaps in care, and leveraging industry-standard guideline-directed clinical pathways. Greater access to timely and high-integrity data has also improved the quality of our forecasting, as demonstrated in the ongoing development of our 2025 cost trends. We have favorable medical cost trend development from the second half of 2025 and are seeing slight moderation within patient census so far in 2026.

With that said, given it is early in the year, we believe it remains prudent to maintain our net cost trend outlook of approximately 7% for full year 2026. Our full-risk total care model is delivering clinical and quality outcomes, and driving strong patient and PCP Net Promoter Scores, while demonstrating the ability to effectively manage utilization and medical cost trend. Let me discuss clinical and quality programs, focusing primarily on our clinical execution, which is a core driver for our model. As a reminder, the congestive heart failure, or CHF program, remains the most mature pathway deployed across 90% of our markets. Let me start with why this program is important to patients. Approximately 40%-50% of patients nationally are diagnosed at the time of first admission to the hospital.

That means missed opportunities for earlier detection, leading to less than ideal care and unnecessary hospital costs. The second thing we know about heart failure is that less than 10% of patients are actually on the right therapies. Through a proactive and guideline-directed approach, our physician partners have been able to shift CHF diagnosis to earlier in the care continuum, with inpatient first diagnosis rates improving from approximately 25% to less than 5%. Less than 5% of heart failure diagnoses are now in the inpatient setting. Additionally, we are expanding our pharmacy-integrated management approach for heart failure patients across the network and observing positive trends in guideline-directed therapy rates, which we expect to improve functional outcomes for patients and prevent downstream complications of disease that lead to admissions.

Current results reflect the combination of our early detection and diagnosis supported by in-office or increased access to diagnostic